CurrentBlue Cross Blue Shield - MassachusettsPolicy 200

Transanal endoscopic microsurgery (TEM) for rectal tumors — coverage and authorization

Medical policy governing coverage and authorization for transanal endoscopic microsurgery (TEM/TEMS) for rectal adenomas and early rectal adenocarcinomas for Blue Cross Blue Shield - Massachusetts commercial and Medicare products.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyTransanal endoscopic microsurgery (TEM) for rectal tumors — coverage and authorization

Policy CodePolicy 200

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionObtain precertification/preauthorization when the procedure is performed inpatient; for outpatient services prior authorization is not required for many products.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

0184TProcedure code listed

C20, D01.2, D12.8Diagnosis codes listed

RequiredInpatient prior auth

Often not requiredOutpatient prior auth

Non-covered when criteria unmetInvestigational stance

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Transanal Endoscopic Microsurgery (TEM)

Adenomas (Benign neoplasms)

Covered when ALL of the following are met for rectal adenomas

Rectal adenoma coverage: Transanal endoscopic microsurgery for treatment of rectal adenomas, including recurrent adenomas that cannot be removed using other means of local excision, is considered medically necessary.

Support: low postoperative complication rates and low recurrence in case series, but comparative benefit versus standard procedures is uncertain.

Clinical T1 Rectal Adenocarcinoma

Covered when ALL of the following are met for clinical stage T1 rectal adenocarcinomas

T1 rectal adenocarcinoma coverage: Tumor located in the middle or upper rectum; AND well or moderately differentiated (G1 or G2) on biopsy; AND no lymphadenopathy; AND tumor involves less than one-third of the rectal circumference; AND the tumor cannot be removed by other means of local excision.location: middle or upper rectum; grade: G1 or G2; lymphadenopathy: absent; size: <1/3 circumference

TEM considered medically necessary only when all criteria are met.

Investigational / Not Medically Necessary Indications

Not covered when ANY of the following apply

Investigational indications: Rectal tumors that do not meet the specified criteria for location, grade, absence of lymphadenopathy, or size (<1/3 circumference) are considered investigational and are not covered.

Evidence is insufficient to demonstrate improved net health outcome for these indications (higher local recurrence and uncertain impact on survival).

Transanal endoscopic microsurgery (TEM) for rectal tumors that do not meet the specified medical necessity criteria is considered investigational and is excluded from coverage. These investigational indications include tumors that fail to meet the required anatomic location, histologic grade, absence of lymphadenopathy, or size threshold (less than 1/3 of the rectal circumference).

For early (clinical T1) rectal adenocarcinoma, available evidence includes small randomized trials, nonrandomized comparative studies, single-arm case series, and systematic reviews. TEM is associated with fewer postoperative complications but with higher local recurrence rates compared with radical surgery; some analyses have suggested possible increases in metastatic disease and at least one systematic review reported improved overall survival with radical surgery. Because the evidence base is limited in size and quality, the comparative benefit of TEM on net health outcome remains insufficient to conclude superiority or equivalence to standard radical surgery or radiotherapy approaches.

Coding

Covered CPT Codes (when criteria met)CPTCovered

0184T

Excision of rectal tumor, transanal endoscopic microsurgical approach (i.e., TEMS)

Diagnosis codes considered medically necessary with CPT 0184TICD-10

C20	Malignant neoplasm of rectum
D01.2	Carcinoma in situ of rectum
D12.8	Benign neoplasm of rectum

Provider Actions, Documentation & Authorization

Prior Authorization

Prior Authorization Required

Precertification/preauthorization is required when the procedure is performed inpatient. For outpatient settings, prior authorization requirements vary by product — see payer-specific outpatient prior authorization guidance.

Inpatient procedures: precertification/preauthorization IS REQUIRED for all products.
Outpatient procedures: Prior authorization not required for Commercial PPO/Indemnity and Medicare HMO/PPO Blue for routine outpatient TEM; verify product-specific rules before scheduling.

Denial Risk

Treatment Sequencing and Investigational Indications

Transanal endoscopic microsurgery (TEMS) may be considered medically necessary for specified rectal adenomas and select T1 rectal adenocarcinomas that meet policy clinical criteria. Procedures for rectal tumors that do not meet those criteria are investigational and may be denied.

Background

Transanal endoscopic microsurgery (TEM) is a minimally invasive technique for local excision of rectal lesions that extends the surgeon’s reach beyond direct visualization. TEM can be used to remove large benign polyps not amenable to endoscopic resection and is employed selectively for some early malignant lesions. The approach is an alternative to open or laparoscopic excision and aims to avoid the morbidity of radical rectal surgery while providing a full-thickness local excision.

Definitions

TEM — Transanal Endoscopic Microsurgery

TermTransanal endoscopic microsurgery (TEM)

DefinitionA minimally invasive approach to local excision of rectal lesions using a specialized magnifying rectoscope with ports for insufflation, instrumentation, and irrigation.

Indications (examples)Used for benign conditions such as large rectal polyps not removable by colonoscope, retrorectal masses, rectal strictures, rectal fistulae, and pelvic abscesses; also used selectively for malignant polyps.

Clinical considerationsCan avoid morbidity and mortality of major rectal surgery (eg, fecal incontinence from sphincter stretching); may be performed under general or regional anesthesia.

LimitationsNot widely used in the U.S. due to a steep learning curve and limited indications; many rectal cancers require wide excision and are not amenable to local resection.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyTransanal endoscopic microsurgery (TEM) for rectal tumors — coverage and authorization

Policy CodePolicy 200

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionObtain precertification/preauthorization when the procedure is performed inpatient; for outpatient services prior authorization is not required for many products.

SourceLink

On This Page

TEMS considered MEDICALLY NECESSARY for rectal adenomas (including recurrent adenomas not removable by other local excision methods).
TEMS considered MEDICALLY NECESSARY for clinical stage T1 rectal adenocarcinomas only when ALL of the following are met: located in middle/upper rectum; well or moderately differentiated (G1 or G2) by biopsy; no lymphadenopathy; < 1/3 circumference involvement.
TEMS for rectal tumors not meeting the above criteria is INVESTIGATIONAL and may be denied.

Documentation Required

Required Coding and Medical Necessity Documentation

Submit CPT code 0184T with supporting ICD-10 diagnosis codes and documentation that demonstrates the medical necessity criteria are met. Include pathology/biopsy reports, imaging that documents absence of lymphadenopathy, tumor location and size (circumferential involvement), and tumor grade when applicable.

Report CPT 0184T — Excision of rectal tumor, transanal endoscopic microsurgical approach.
Submit an appropriate ICD-10 diagnosis code (e.g., C20, D01.2, D12.8) that supports the indication.
Attach operative reports, pathology/biopsy results, and preoperative imaging (to confirm no lymphadenopathy and tumor location/size).
Document that the tumor meets all medical necessity criteria (location, differentiation grade, lymph node status, <1/3 circumference) when claiming coverage.

Denial Risk

Inpatient Precertification Required

If the procedure is performed inpatient and precertification is not obtained, the claim may be denied for lack of authorization. Confirm and obtain inpatient precertification per product requirements to avoid denial risk.

Inpatient precertification/preauthorization is required for all products; failure to precertify may result in claim denial.